Sutro Biopharma Q4 EPS $(5.29) Misses $(4.35) Estimate, Sales $11.647M Beat $8.341M Estimate

Sutro Biopharma (NASDAQ: STRO) reported a Q4 loss of $(5.29) per share, missing the analyst estimate of $(4.35) by 21.58%, and reflecting a 40.56% increase in losses compared to $(8.90) per share in the same quarter last year. The company achieved quarterly sales of $11.647 million, surpassing the $8.341 million estimate by 39.64%, although this represents a 21.35% decrease from $14.809 million in the prior year.